Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,325 questions in 216 reviews · Airways
current versionsNo studies 249 · 10.7%Ungraded 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Macrolides vs no intervention Mortality · adults with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 2 studies · 88 participants | Very low |
Macrolides vs no intervention QoL SGRQ: endpoint total score Scale from 0 to 100 · adults with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 2 studies · 89 participants | Moderate |
Macrolides vs no intervention QoL SGRQ: change in total score Scale from 0 to 100 · adults with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 30 participants | Moderate |
Macrolides vs placebo Exacerbation frequency · children with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | IRR 0.5 | 1 study · 89 participants | Low |
Macrolides vs placebo Hospitalisation: all‐cause · children with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | OR 0.28 [0.07, 1.11] | 1 study · 89 participants | Low |
Macrolides vs placebo Serious adverse events · children with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | OR 0.43 [0.17, 1.05] | 1 study · 89 participants | Low |
Macrolides vs placebo Mortality · children with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 42 participants | Low |
Macrolides vs placebo Quality of life not reported · children with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Macrolides vs no intervention Exacerbations ‐ not reported · children with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Macrolides vs no intervention Hospitalisation ‐ not reported · children with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Macrolides vs placebo Hospitalisation: all cause · adults with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | OR 0.56 [0.19, 1.62] | 2 studies · 151 participants | Low |
Macrolides vs no intervention Serious adverse events ‐ not reported · children with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Macrolides vs no intervention Mortality · children with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 34 participants | Low |
Macrolides vs no intervention Quality of life ‐ not reported · children with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Macrolides vs placebo Serious adverse events · adults with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | OR 0.49 [0.2, 1.23] | 3 studies · 326 participants | Low |
Macrolides vs placebo All‐cause mortality · adults with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 7 studies · 540 participants | Low |
Macrolides vs placebo Quality of life: endpoint · adults with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 68 participants | Moderate |
Macrolides vs placebo Quality of life: change · adults with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 4 studies · 305 participants | Low |
Macrolides vs no intervention ≥ 1 exacerbation · adults with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | OR 0.31 [0.08, 1.15] | 1 study · 43 participants | Moderate |
Macrolides vs no intervention Hospitalisations ‐ not reported · adults with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Macrolides vs no intervention Serious adverse events ‐ not reported · adults with bronchiectasis Macrolide antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Oral + inhaled dual therapy vs oral monotherapy Successful treatment of exacerbation: number of participants cured. Outcome assessed on day 42 · bronchiectasis Dual antibiotics for bronchiectasis (2018) · Cochrane | OR 0.66 [0.22, 2.01] | 1 study · 53 participants | Very low |
Oral + inhaled dual therapy vs oral monotherapy Successful treatment of exacerbation: number of participants with P aeruginosa eradication. Outcome assessed on day 21 · bronchiectasis Dual antibiotics for bronchiectasis (2018) · Cochrane | OR 2.33 [0.66, 8.24] | 1 study · 53 participants | Very low |
Oral + inhaled dual therapy vs oral monotherapy Serious adverse events. Outcome assessed on day 42 · bronchiectasis Dual antibiotics for bronchiectasis (2018) · Cochrane | OR 0.48 [0.08, 2.87] | 1 study · 53 participants | Very low |
Oral + inhaled dual therapy vs oral monotherapy Treatment response: relapse (day 42). Outcome assessed on day 42 · bronchiectasis Dual antibiotics for bronchiectasis (2018) · Cochrane | OR 0.57 [0.12, 2.69] | 1 study · 53 participants | Very low |
Oral + inhaled dual therapy vs oral monotherapy Microbiological response: eradicated. Outcome assessed on day 21 · bronchiectasis Dual antibiotics for bronchiectasis (2018) · Cochrane | OR 2.4 [0.67, 8.65] | 1 study · 49 participants | Very low |
Oral + inhaled dual therapy vs oral monotherapy Hospitalisations · bronchiectasis Dual antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Oral + inhaled dual therapy vs oral monotherapy Death · bronchiectasis Dual antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Oral + inhaled dual therapy vs oral monotherapy Quality of life · bronchiectasis Dual antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Self‐management vs usual care Health‐related quality of life · people with non‐cystic fibrosis bronchiectasis Self‐management for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |
Self‐management vs usual care Health‐related quality of life · people with non‐cystic fibrosis bronchiectasis Self‐management for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 60 participants | Low |
Self‐management vs usual care Exacerbations requiring antibiotics · people with non‐cystic fibrosis bronchiectasis Self‐management for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Self‐management vs usual care Serious adverse events: mortality · people with non‐cystic fibrosis bronchiectasis Self‐management for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 20 participants | Ungraded |
Self‐management vs usual care Hospital admissions (number admitted at least once) · people with non‐cystic fibrosis bronchiectasis Self‐management for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 20 participants | Ungraded |
Self‐management vs usual care Lung function · people with non‐cystic fibrosis bronchiectasis Self‐management for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |
Self‐management vs usual care Self‐efficacy · people with non‐cystic fibrosis bronchiectasis Self‐management for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 60 participants | Low |
Self‐management vs usual care Economic costs · people with non‐cystic fibrosis bronchiectasis Self‐management for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Fluoroquinolones vs amoxicillin Exacerbations · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Polymyxins vs aminoglycosides Response rate ‐ improvement in sputum purulence · adults aged 18 years and above with diagnosis of bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | OR 0.16 [0.01, 3.85] | 1 study · 20 participants | Very low |
Polymyxins vs aminoglycosides Response rate ‐ P aeruginosa eradication · adults aged 18 years and above with diagnosis of bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | OR 1.4 [0.36, 5.35] | 1 study · 35 participants | Very low |
Polymyxins vs aminoglycosides Deaths · adults aged 18 years and above with diagnosis of bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |
Polymyxins vs aminoglycosides Quality of life · adults aged 18 years and above with diagnosis of bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Fluoroquinolones vs amoxicillin Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 2 studies · 83 participants | Low |
Fluoroquinolones vs amoxicillin Response rate ‐ treatment failure · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | OR 0.07 [0.01, 0.32] | 2 studies · 83 participants | Low |
Fluoroquinolones vs amoxicillin Response rate ‐ microbiological response · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | Peto OR 20.09 [2.83, 142.59] | 1 study · 16 participants | Low |
Fluoroquinolones vs amoxicillin Response rate ‐ improvement in sputum purulence (excellent) · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | OR 2.35 [0.96, 5.72] | 2 studies · 83 participants | Very low |
Fluoroquinolones vs amoxicillin Deaths · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 2 studies · 83 participants | Low |
Fluoroquinolones vs amoxicillin Quality of life · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Polymyxins vs aminoglycosides Exacerbation · adults aged 18 years and above with diagnosis of bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | NR | No studies |
Polymyxins vs aminoglycosides Serious adverse events · adults aged 18 years and above with diagnosis of bronchiectasis Head‐to‐head trials of antibiotics for bronchiectasis (2018) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |